The global yeast infection treatment market was valued at USD 6158.8 million in 2023. The market is estimated to surge at a CAGR of 5.0%, reaching a valuation of USD 10031.3 million in 2034. The primary factors driving this market's expansion include the advent of novel fungal illnesses, as well as the rise in autoimmune disorders and yeast infections.
| Attributes | Key Insights |
|---|---|
| Anticipated Market Value (2023A) | USD 6158.8 million |
| Estimated Yeast Infection Treatment Market Size (2024E) | USD 6479.8 million |
| Projected Yeast Infection Treatment Market Value (2034F) | USD 10031.3 million |
| Value-based Yeast Infection Treatment Market CAGR (2024 to 2034) | 5.0% |
Market expansion is projected to be fueled by the global economic recovery, which enables consumers to access better and higher-quality healthcare. Increasing patient awareness and knowledge of yeast infections is a buffer for market expansion through 2034.
Market growth is also anticipated to be fueled by government support for research and development activities in creating antifungal drugs. In addition, the market is expected to rise significantly due to the funding from the government for medical research & development and innovative therapies for yeast infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Yeast infection treatment market sales account for around 39.4% of the share globally. The market was valued at USD 6158.8 million in 2023. The global yeast infection treatment market recorded a historic CAGR of 3.9% from 2019 to 2023.
Global yeast infection treatment market expansion is anticipated to be driven by an increasing number of yeast infection cases, particularly in women. As of 2022, around 70% of women have encountered vulvovaginal candidiasis at least once in their lives, and 8% of them have had recurrent vulvovaginal candidiasis, per NCBI studies.
Yeast infections, also known as Candida infections, have become more common worldwide. Several variables, such as weakened immune systems, broad-spectrum antibiotics, and lifestyle changes, contribute to the rising incidence of yeast infections.
Public education and awareness of yeast infections have received more attention recently. Pharmaceutical companies and healthcare providers have initiated awareness campaigns to educate the public about the symptoms and preventive actions associated with yeast infections.
Through research and development, ongoing efforts have been made to look into novel therapeutic approaches and formulations for yeast infection treatment.
Treatments for yeast infections are widely available worldwide, and access to medications and healthcare has improved for emerging economies. Population growth, urbanization, and improvements in the healthcare system are some of the factors behind this surge.
Principal Consultant
The table below highlights the anticipated growth rates of different countries. Among these, India is expected to remain a highly lucrative market for yeast infection treatment, exhibiting a CAGR of 5.8%. China and Japan are anticipated to follow with CAGRs of 5.4% and 5.7%, respectively.
| Countries | Projected CAGR (2024 to 2034) |
|---|---|
| United States | 5.2% |
| China | 5.4% |
| Germany | 4.9% |
| India | 5.8% |
| Japan | 5.7% |
The United States dominated North America’s yeast infection treatment market with a share of around 90.5% in 2022. It is expected to continue to experience the same growth rate throughout the forecast period.
Understanding population preferences is critical for pharmaceutical companies operating in the yeast infection treatment market. The United States yeast infection treatment market will likely expand due to population growth, aging population, and increasing health consciousness.
In the United States, prescription and over-the-counter antifungal drugs are frequently used to treat yeast infections. Oral antifungal treatments such as fluconazole, suppositories, and topical antifungal creams are set to be common medications in the United States.
Candida auris poses a concern to patients in healthcare facilities across Europe, particularly in Germany, because of its potential to cause epidemics and its antifungal tolerance. Due to ongoing efforts to raise national awareness of yeast infection, prevention and control measures, the market is expected to surge in Germany.
Over-the-counter (OTC) medications, such as suppositories and antifungal lotions, give people self-treatment choices. This accessibility influences the dynamics of the market as a whole.
Germany-based healthcare groups regularly participate in awareness programs to raise public knowledge of yeast infections. This details risk factors, symptoms, and the significance of consulting a medical expert for yeast infection treatment.
China reached a valuation of USD 301.7 million, withholding a significant market share of around 28.9% by 2022. China, in particular, is home to a variety of unknown yeasts that have the potential to be pathogenic in exposed hosts.
One of the key factors influencing the market for yeast infection treatment is the regulatory landscape in China, which includes the approval procedure for new medications and therapies. Market dynamics can be affected by consumer preferences for particular brands or treatment types and the rising popularity of natural or home cures.
Economic considerations can affect the population's accessibility to treatments for yeast infections, including healthcare spending, insurance coverage, and pharmaceutical prices. China continues to lead the world in the research & development of antifungal drugs, including investigating novel compounds and treatment approaches.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below signifies leading sub-categories under the route of administration, form, and distribution channel segment categories in the yeast infection treatment market. The oral segment is expected to surge at a CAGR of 5.2% in the evaluation period. Under the form category, the tablets/ capsules segment is projected to rise at a CAGR of 5.4% by 2034.
| Route of Administration | Value-based CAGR |
|---|---|
| IV/IM | 5.4% |
| Oral | 5.2% |
Based on the route of administration, the oral segment has driven the market by holding a significant share of around 54.6% in 2022. Due to its benefits, including non-invasiveness, patient compliance, and ease of drug administration, it is the most favored method in the market.
The oral route of administration is recommended for systemic antifungal treatment since it enables convenient and patient-friendly dosage. The drug can be taken by the patient at home, and this method of delivery is frequently preferred by the patient over intravenous therapy.
When prescribing oral antifungal drugs, healthcare providers should consider patient compliance, drug interactions, and possible side effects. Furthermore, new oral antifungal medications are being introduced into the market to treat yeast infections as a result of ongoing research and development activities.
| Form | Value-based CAGR |
|---|---|
| Tablets/ Capsules | 5.4% |
| Cream / Ointments | 5.0% |
Based on form, the tablets/capsules segment has led the market by holding a remarkable share of 45.8% in 2022. Tablets are available in different shapes and have a longer shelf life. Also, they can withstand a higher dosage of an active chemical.
The specific antifungal medication, patient preferences, and the stability & bioavailability of the formulation are a handful of the elements that influence the demand for tablets and capsules. Tablets and capsules include benefits such as precise dosing, simplicity of storage, and enhanced patient compliance, which would drive sales.
| Distribution Channel | Value-based CAGR |
|---|---|
| Online Sales | 6.0% |
| Retail Pharmacies/ Drug Stores | 5.5% |
Based on distribution channels, retail pharmacies/drug stores have driven the global market, withholding a share of around 31.2% in 2022. Working long hours, drive-through facilities, and a wide variety of prescription and over-the-counter pharmaceuticals are the key drivers boosting the demand for retail pharmacies and drug stores.
Several e-commerce sites and online pharmacies let customers buy products for treating yeast infections straight from their websites. This covers popular websites such as Walmart, Amazon, and specialized online pharmacies.
Conventional merchants frequently offer an online presence that enables customers to order items for treating yeast infections and have them delivered to their homes. This covers both big-box pharmacies and independent health and wellness stores.
The market as a whole is fragmented due to the several players in the yeast infection treatment sector. In order to fulfill consumer demand and expand their client base, key firms are launching new products, forming partnerships & collaborations, and engaging in mergers & acquisitions.
Instances of key developmental strategies by leading players in the yeast infection treatment market are given below:
| Attribute | Details |
|---|---|
| Estimated Yeast Infection Treatment Market Size (2024) | USD 6479.8 million |
| Projected Yeast Infection Treatment Market Value (2034) | USD 10031.3 million |
| Anticipated Growth Rate (2024 to 2034) | 5.0% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; and Middle East and Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Rest of Latin America, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, GCC, South Africa, North Africa and Rest of Middle East and Africa |
| Key Market Segments Covered | Treatment Type, Indication, Route of Administration, Form, Distribution Channel, and Region |
| Key Companies Profiled | Astellas Pharma Inc.; Astra Zeneca; Abbott Laboratories; Allergan; Brundavan Laboratories Private Limited; Bayer; Corden Pharma; Merck & Co., Inc.; Novartis; Pfizer Inc.; Synmedic Laboratories; Sanofi |
The yeast infection treatment market size is estimated to reach USD 6158.8 million in 2023.
The target market size is expected to reach USD 10031.3 million in 2034.
The emergence of new fungal infections and increasing use of antibiotics would fuel growth.
Astellas Pharma Inc., Astra Zeneca, and Abbott Laboratories are the leading players.
The market for yeast infection treatment expanded at a CAGR of 3.9%.
Yeast infection treatment demand is set to surge at a 5.0% CAGR through 2034.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value USD million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type 7.1. Azoles 7.2. Polygene 7.3. Echinocandin 7.4. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication 8.1. Genital Candidiasis 8.2. Invasive Candidiasis 8.3. Oropharyngeal/Esophageal Candidiasis (Thrush) 8.4. Others 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 9.1. Oral 9.2. Topical 9.3. IV/IM 9.4. Other 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Form 10.1. Powders 10.2. Creams/Ointments 10.3. Tablets/Capsules 10.4. Others 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 11.1. Retail Pharmacies/Drug Stores 11.2. Hospital Pharmacies 11.3. Specialty Stores 11.4. Online Sales 11.5. Others (Hypermarkets/Conventional Stores) 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. East Asia 12.5. South Asia 12.6. Oceania 12.7. Middle East and Africa 13. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15. Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17. South Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18. Oceania Market 2019 to 2023 and Forecast 2024 to 2034 19. Middle East and Africa (MEA) Market Analysis 2019 to 2023 and Forecast 2024 to 2034 20. Market Structure Analysis 21. Competition Analysis 21.1. Abbott Laboratories 21.2. Astellas Pharma Inc. 21.3. Astra Zeneca 21.4. Allergan 21.5. Brundavan Laboratories Private Limited 21.6. Bayer 21.7. Corden Pharma 21.8. Merck & Co., Inc. 21.9. Novartis 21.10. Pfizer Inc. 21.11. Synmedic Laboratories 21.12. Sanofi 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Yeast Infection Treatment Market
